<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methoxsalen</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00553</strong>&#160; (APRD00157)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms <span class="caps">DNA</span> adducts in the presence of ultraviolet A irradiation. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00553/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00553/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00553.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00553.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00553.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00553.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00553.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00553">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ammoidin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Methoxalen</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Methoxsalen</td><td>German</td><td>INN</td></tr><tr><td>M&#233;thoxsal&#232;ne</td><td>French</td><td>INN</td></tr><tr><td>Xanthotoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Xanthotoxine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Xanthoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zanthotoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Deltasoralen</td><td>Delta</td></tr><tr><td>Meladinine</td><td>CLS Pharma</td></tr><tr><td>Oxsoralen</td><td>Valeant</td></tr><tr><td>Oxsoralen-Ultra</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Uvadex</td><td>Therakos</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/photosensitizing-agents">Photosensitizing Agents</a></li>
<li><a href="/mesh/cross-linking-reagents">Cross-Linking Reagents</a></li>
<li><a href="/mesh/pigmenting-agents">Pigmenting Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>298-81-7</td></tr><tr><th>Weight</th><td>Average: 216.1895<br>Monoisotopic: 216.042258744</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>8</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>QXKHYNVANLEOEG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">9-methoxy-2H-furo[3,2-g]chromen-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C2OC(=O)C=CC2=CC2=C1OC=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Coumarins and Derivatives</td></tr><tr><th>Subclass</th><td>Furanocoumarins</td></tr><tr><th>Direct parent</th><td>8-Methoxypsoralens</td></tr><tr><th>Alternative parents</th><td>Benzopyrans; Benzofurans; Anisoles; Pyranones and Derivatives; Alkyl Aryl Ethers; Furans; Polyamines</td></tr><tr><th>Substituents</th><td>benzopyran; benzofuran; anisole; phenol ether; pyranone; alkyl aryl ether; pyran; benzene; furan; polyamine; ether</td></tr><tr><th>Classification description</th><td>This compound belongs to the 8-methoxypsoralens. These are psoralens containing a methoxy group attached at the C8 position of the psoralen group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of psoriasis and vitiligo</td></tr><tr><th>Pharmacodynamics</th><td>Methoxsalen selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Methoxsalen-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.</td></tr><tr><th>Mechanism of action</th><td>After activation it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>In both mice and man, methoxsalen is rapidly metabolized.  Approximately 95% of the drug is excreted as a series of metabolites in the urine within 24 hours (Pathak et al. 1977).</td></tr><tr><th>Half life</th><td>Approximately 2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9921</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9211</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6185</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5518</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5468</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7921</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6236</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9629</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5968</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.9316</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.774</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7381</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.886
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9552
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7255
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4054 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9563
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9638
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Sandoz inc</li>
<li>Therakos inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.therakos.com">Therakos Inc.</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Topical</td><td></td></tr><tr><td>Lotion</td><td>Topical</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of psoralene</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Methoxsalen. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Methoxsalen is initiated, discontinued or if the dose is changed.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>The strong CYP1A2 inhibitor, Methoxsalen, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Methoxsalen is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food or milk, or in two divided doses 30 minutes apart to decrease nausea.</li></ul></td></tr></tbody></table>